🟢 Adaptive Biotechnologies Surges 6.05% Following Analyst Price Target Increase and Reiterated 'Buy' Rating

Adaptive Biotechnologies is trading at $21.38 (+6.05%) today, following a positive analyst update.

• The company's 12-month average price target was raised to $20.57, implying approximately 2% potential upside from the previous day's closing price.
• Analysts maintain a "Buy" consensus rating for ADPT, with 7 out of 8 analysts recommending a "Buy".